Essex Investment Management Co. LLC acquired a new stake in Audentes Therapeutics, Inc. (NASDAQ:BOLD) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 17,481 shares of the biotechnology company’s stock, valued at approximately $490,000. Essex Investment Management Co. LLC owned about 0.06% of Audentes Therapeutics at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. Wells Fargo & Company MN boosted its holdings in shares of Audentes Therapeutics by 278.5% in the 1st quarter. Wells Fargo & Company MN now owns 7,747 shares of the biotechnology company’s stock valued at $132,000 after acquiring an additional 5,700 shares during the last quarter. Nationwide Fund Advisors boosted its holdings in shares of Audentes Therapeutics by 288.9% in the 2nd quarter. Nationwide Fund Advisors now owns 8,594 shares of the biotechnology company’s stock valued at $164,000 after acquiring an additional 6,384 shares during the last quarter. Citadel Advisors LLC purchased a new stake in shares of Audentes Therapeutics in the 1st quarter valued at $184,000. State of Wisconsin Investment Board purchased a new stake in shares of Audentes Therapeutics in the 2nd quarter valued at $210,000. Finally, Rhumbline Advisers purchased a new stake in shares of Audentes Therapeutics in the 2nd quarter valued at $252,000. 77.09% of the stock is currently owned by institutional investors and hedge funds.

In other Audentes Therapeutics news, VP Suyash Prasad sold 8,000 shares of the stock in a transaction on Friday, September 1st. The shares were sold at an average price of $21.44, for a total transaction of $171,520.00. Following the transaction, the vice president now directly owns 8,000 shares of the company’s stock, valued at $171,520. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, SVP Mary Newman sold 10,000 shares of the stock in a transaction on Thursday, August 24th. The shares were sold at an average price of $20.00, for a total transaction of $200,000.00. Following the transaction, the senior vice president now directly owns 10,000 shares in the company, valued at $200,000. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 766,500 shares of company stock worth $21,443,730. Insiders own 47.30% of the company’s stock.

WARNING: This story was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this story on another site, it was illegally stolen and republished in violation of international copyright & trademark laws. The legal version of this story can be viewed at https://www.thecerbatgem.com/2017/11/05/17481-shares-in-audentes-therapeutics-inc-bold-purchased-by-essex-investment-management-co-llc.html.

BOLD has been the topic of several recent research reports. Bank of America Corporation reaffirmed a “buy” rating and issued a $33.00 price objective (up from $23.00) on shares of Audentes Therapeutics in a report on Friday, September 22nd. Zacks Investment Research raised shares of Audentes Therapeutics from a “hold” rating to a “buy” rating and set a $23.00 price objective on the stock in a report on Monday, July 17th. ValuEngine raised shares of Audentes Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, August 24th. Raymond James Financial, Inc. began coverage on shares of Audentes Therapeutics in a report on Thursday, October 12th. They set a “market perform” rating on the stock. Finally, Evercore ISI began coverage on shares of Audentes Therapeutics in a report on Wednesday, August 16th. They set an “outperform” rating and a $23.00 price target on the stock. One investment analyst has rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $25.71.

Shares of Audentes Therapeutics, Inc. (BOLD) opened at $25.02 on Friday. Audentes Therapeutics, Inc. has a twelve month low of $13.13 and a twelve month high of $33.43.

Audentes Therapeutics (NASDAQ:BOLD) last announced its quarterly earnings results on Thursday, August 10th. The biotechnology company reported ($0.87) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.77) by ($0.10). analysts anticipate that Audentes Therapeutics, Inc. will post -3.53 earnings per share for the current year.

Audentes Therapeutics Profile

Audentes Therapeutics, Inc is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).

Want to see what other hedge funds are holding BOLD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Audentes Therapeutics, Inc. (NASDAQ:BOLD).

Institutional Ownership by Quarter for Audentes Therapeutics (NASDAQ:BOLD)

Receive News & Stock Ratings for Audentes Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics Inc. and related stocks with our FREE daily email newsletter.